In Episode 49 of the Pound of Cure Weight Loss Podcast, Dr. Weiner and Zoe examine the steep costs of obesity medications like Wegovy, the influence of pharmacy benefit managers (PBMs), and the role of big pharmaceutical companies in shaping healthcare. Highlighting recent Senate hearings led by Bernie Sanders with Novo Nordisk’s CEO Lars Fruergaard Jørgensen, this episode sheds light on how the current system prioritizes profit, often at the expense of patients’ access to care.

Wegovy Cost: Breaking Down High Prices in the U.S.

Wegovy, a GLP-1 medication, costs around $1,349 per month in the U.S., while in other countries like the U.K., prices are as low as $92. Dr. Weiner explains that this discrepancy illustrates a broken healthcare model, where the U.S. market fuels corporate profit but leaves millions unable to afford essential treatments. With 72% of Novo Nordisk’s revenue coming from U.S. sales, the company’s pricing strategy relies on American consumers, who are left paying significantly more for the same medications.

Big Pharma’s Influence on Policy and Profits

This episode delves into Big Pharma’s control over drug pricing, particularly the stark contrast between their research and development costs and their profits. For example, while Novo Nordisk spent $21 billion on R&D, they spent twice as much—$44 billion—on stock buybacks and dividends. Dr. Weiner highlights how political influence plays a crucial role, with both major parties receiving substantial donations from pharmaceutical companies, leading to stalled efforts in drug price regulation and patient access.

Pharmacy Benefit Managers (PBMs): Hidden Gatekeepers Driving Up Costs

PBMs, the intermediaries between insurers and pharmacies, are supposed to negotiate better prices, but Dr. Weiner and Zoe point out that they often drive costs higher through hidden fees. In many cases, PBMs have financial incentives to push higher-priced drugs, creating a “pay-to-play” system that limits patient access. For example, PBMs profit by taking a percentage of negotiated drug price savings, meaning higher drug list prices generate greater profits for them. Dr. Weiner underscores how PBMs complicate and inflate pricing, making it even harder for patients to get GLP-1 medications through insurance.

Do We Need Health Insurance Companies and PBMs?

Dr. Weiner questions the necessity of insurance companies and PBMs in the healthcare system, arguing that they don’t provide direct patient care yet extract billions from the system. He suggests that healthcare can function without these financial middlemen, allowing for a more transparent, patient-centered system where costs are lower and patients have better access to needed treatments.

The Morality of Obesity Treatment Costs

The episode closes with Dr. Weiner and Zoe discussing the stigma surrounding obesity and the moral implications of restricting access to life-changing medications like Wegovy. They emphasize that obesity is a complex, chronic disease requiring comprehensive treatment, not simply a “lifestyle” issue. Dr. Weiner advocates for recognizing obesity treatment as essential, which could lead to a shift in how these medications are accessed and covered.

Final Takeaways

While the healthcare landscape remains challenging, Dr. Weiner believes patient advocacy, legislative changes, and innovation can improve access to these life-saving treatments. This episode offers insights into navigating the current system while emphasizing the need for systemic change to prioritize patient health over profits.

In Episode 48 of the Pound of Cure Weight Loss podcast, Dr. Matthew Weiner and Zoe Schroeder explore the future of compounded GLP-1 medications, the dangers of the health halo effect, and debunk common diet myths that often lead to confusion for those trying to lose weight.

Compounded GLP-1 Medications: A Controversial Solution on the Brink of Extinction

Dr. Weiner and Zoe kick off the discussion by addressing the fate of compounded GLP-1 medications. Medications like Zepbound and Wegovy, FDA-approved for obesity, have faced shortages, leading to the rise of compounded alternatives. These non-FDA-regulated versions, sourced from China and mixed in US compounding pharmacies, have been a lifeline for patients who can't access the brand-name medications.

However, Dr. Weiner highlights that these compounded versions may soon become unavailable due to regulatory changes. Compounded GLP-1 medications can only be produced during shortages of the original drugs and with supply stabilizing, their production may soon be banned. Patients currently relying on compounded alternatives will need to explore other options, such as the Pound of Cure Weight Loss Platinum Program.

Diet Myths: Dispelling Common Misconceptions

Dr. Weiner and Zoe also tackle pervasive diet myths, particularly the belief that weight loss is simply a matter of calorie counting. This outdated “calories in, calories out” philosophy ignores the body’s hormonal responses to food. They explain that hormones like GLP-1, ghrelin and leptin play crucial roles in regulating hunger and metabolism, which is why focusing purely on calorie restriction often leads to failure.

Another myth they address is the idea that fat is the enemy. While processed and animal fats should be avoided, healthy fats from sources like avocados, nuts, and seeds are vital for long-term weight management. Additionally, Zoe clarifies that not all carbs are bad — distinguishing between refined carbs and whole-food sources like vegetables and legumes is key for sustained energy and weight loss.

The Health Halo Effect: How Marketing Tricks Consumers

The health halo effect is another topic of discussion, focusing on how food marketing can deceive consumers into making poor health choices. Labels such as “organic,” “vegan,” “low-carb” or “gluten-free” often create the illusion of health, even when the products are filled with sugar or unhealthy ingredients.

Dr. Weiner and Zoe stress the importance of avoiding these traps by focusing on real, unprocessed foods like vegetables, lean proteins, fruits, nuts, beans and seeds. This approach helps ensure that you’re making choices that genuinely support your health and weight loss efforts, rather than falling for misleading marketing.

Conclusion

In this episode, Dr. Weiner and Zoe offer valuable insights into the future of compounded GLP-1 medications, clarify persistent diet myths, and explain how the health halo effect misleads consumers. As the regulatory landscape changes and food marketing continues to evolve, staying informed and focusing on a balanced, whole-food diet is crucial to achieving long-term success in your weight loss journey.

In Episode 47 of the Pound of Cure Weight Loss Podcast, Dr. Matthew Weiner and Zoe Schroeder, RD dive into weight loss topics like compounded GLP-1 medications, ultra-processed foods and their link to heart disease, and processed meat alternatives.

Ultra-processed Foods: Are Some Worse Than Others?

A recent study published in The Lancet found that ultra-processed foods make up a shocking 73% of the U.S. food supply, with significant consequences for heart health.

Dr. Weiner and Zoe discuss how this study highlighted an 11% increased risk of heart disease for those who consumed the most ultra-processed foods. The study particularly focused on the worst offenders: processed meats and sugar-sweetened beverages. These foods were shown to have the strongest links to heart disease.

One fascinating finding from the study is that not all ultra-processed foods have the same impact. When processed meats and sugary drinks are removed from the equation, the difference in heart disease risk between people who eat a lot of ultra-processed foods and those who don’t becomes much smaller. This reinforces the idea that not all ultra-processed foods are equal when it comes to heart disease risk. Avoiding processed meats and sugary drinks can significantly lower your risk, while focusing on healthier food choices can improve your long-term health.

Nutrition and Heart Health: How to Eat Smarter

When it comes to improving heart health, Dr. Weiner and Zoe offer practical advice on what foods to choose instead of processed meats. Zoe emphasizes the importance of focusing on whole, unprocessed foods, such as:

• Fruits and vegetables: These are packed with vitamins, minerals, and antioxidants that help support heart health.
• Lean animal proteins: Opt for fish, chicken, and lean cuts of red meat as alternatives to fatty cuts of red meat and processed meats. These options provide high-quality protein without the unhealthy fats found in processed meats.
• Nuts and seeds: Rich in healthy fats, fiber, and protein, these are great plant-based alternatives to meat.
• Legumes: Beans, lentils, and chickpeas are nutrient-dense and provide a satisfying source of protein and fiber.

The key is to focus on nutrient-dense, whole foods rather than simply trying to restrict calories or follow fad diets. The Pound of Cure philosophy encourages a shift in mindset toward eating for nutrition and long-term health and weight loss rather than fast weight loss which will, ultimately, come back.

Zoe also mentions the importance of minimizing food noise—the constant mental distraction and cravings for unhealthy foods—by incorporating satisfying, high-quality meals into your daily routine. By making smarter food choices, you can naturally reduce your cravings for processed foods and improve both your heart health and overall well-being.

Replacing processed meats with nutrient-dense foods like fruits, vegetables, lean proteins, nuts, seeds, and legumes is a smart strategy for improving heart health and managing weight.

The Role of GLP-1 Medications in Weight Loss

The episode concludes with an in-depth discussion on the role of GLP-1 medications in weight loss, particularly focusing on the recent shortages and their implications. These medications, like Wegovy and Zepbound, have been highly sought after due to their ability to lower the body’s set point. However, earlier shortages led many patients to seek compounded versions of these drugs.

Dr. Weiner explains that compounded GLP-1 medications are custom-made by compounding pharmacies, which mix the active ingredients (Semaglutide or Tirzepatide) with saline, B12 or other additives.

Release the GLP-1 Vials

The shortage of GLP-1 medications, like Wegovy and Zepbound, was primarily caused by the manufacturing of inj